An Open Label Dose Escalation Phase 1 Clinical Trial of Retinal Gene Therapy for Choroideraemia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 01 Aug 2017
At a glance
- Drugs AAV-REP1 (Primary)
- Indications Choroideremia
- Focus Therapeutic Use
- 01 Aug 2017 According to a NightstaRx media release, data from this study were published in The New England Journal of Medicine in 2016.
- 16 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017, according to ClinicalTrials.gov record.
- 16 Mar 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Feb 2017, according to ClinicalTrials.gov record.